According to local protocols and the literature’s guidance, nearly all patients have received steroids while few were eligible for antiviral or monoclonal therapy due to the severity of respiratory failure; the anti-IL1 anakinra was applied in 44/91 (48.4%) patients during the I wave while the anti-IL6 tocilizumab in two patients during the I and three patients during the IV wave, a low proportion explained by the high risk of bacterial superinfection. The gene discussed is IL6; the disease is respiratory failure.